The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy

Medical Care

Volumn 50, Issue 12, 2012, Pages 1060-1070

  Ahmed, Sara ^a   Berzon, Richard A ^b   Revicki, Dennis A ^c   Lenderking, William R ^c   Moinpour, Carol M ^d   Basch, Ethan ^e   Reeve, Bryce B ^f   Wu, Albert W ^g  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f IL   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

clinical care; comparative effectiveness research; health policy; patient reported outcome

Indexed keywords

BUDESONIDE; CORTICOSTEROID; DESIPRAMINE; FLUOROURACIL; FLUOXETINE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FOLINIC ACID; IMIPRAMINE; NAVELBINE;

ARTICLE; ASTHMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CAREGIVER BURDEN; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOCTOR PATIENT RELATION; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FUNCTIONAL STATUS; HEALTH BEHAVIOR; HEALTH CARE POLICY; HOSPITAL; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL INFORMATION SYSTEM; PATIENT COMPLIANCE; PATIENT INFORMATION; PATIENT REPORTED OUTCOME; PATIENT SATISFACTION; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SHORT FORM 36; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; COMPARATIVE EFFECTIVENESS RESEARCH; HEALTH BEHAVIOR; HEALTH POLICY; HEALTH STATUS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PATIENT-CENTERED CARE; QUALITY OF LIFE; RESEARCH DESIGN; SELF REPORT;

EID: 84870062280     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318268aaff     Document Type: Article

References (135)

1. Canadian INstitute on Patient-Oriented Research. Strategy on Patient- Oriented Research. CIHR 2010. Available : http://www.cihr-irsc.gc.ca/e/41204. html. Accessed August 18, 2010.
2. Whicher DM, Chalkidou K, Dhalla IA, et al. Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers. Milbank Quart. 2009;87:585-606.
3. Comparative effectiveness research and evidence-based decision making across four countries: the U.K., Germany, France, and Australia. The Commonwealth Fund 2009. Available at: http://www.commonwealth fund.org/Content/Publications/Other/2009/Comparative-Effectiveness- Across-Countries.aspx. Accessed May 24, 2011.
4. Bridges JF, Cohen JP, Grist PG, et al. International experience with comparative effectiveness research: case studies from England/Wales and Germany. Adv Health Econ Health Serv Res. 2010;22:29-50.
5. Department of Health and Human Services. The Federal Coordinating Council for Comparative Report to the President 2009. June 30. Available at: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf. Accessed July 28, 2010.
6. US Government Printing Office. HR 3590 Patient Protection and Affordable Care Act. GPO 2010. Available at: http://www.gpo.gov/fdsys/pkg/BILLS- 111hr3590ENR/pdf/BILLS-111hr3590ENR.pdf. Accessed August 18, 2010.
7. US Government Printing Office. Public Law 111-152- Health Care and Education Reconciliation Act of 2010. GPO 2010. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-111publ152/content-detail.html. Accessed August 18, 2010.
8. Patel K. Health reform's tortuous route to the patient-centered outcomes research institute. Health Aff (Millwood). 2010;29:1777-1782.
9. Definition. Patient-Centered Outcomes Research. PCORI, 2012. Available at: http://www.pcori.org/patient-centered-outcomes-research/. Accessed March 23, 2012.
10. FDA. Patient-reported outcomes measures: use in medical product development to support labelling claims. FDA PRO Guidance 2009.
11. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed March 1, 2011.
12. Ganz PA, Goodwin PJ. Quality of life in breast cancer- what have we learned and where do we go from here. In: Lipscomb J, Gotay CC, Snyder C, eds. Outcomes Assessment in Cancer: Measures, Methods, and Applications. Cambridge, UK: Cambridge University Press; 2005:93-126.
13. Litwin MS, Talcott JA. Measuring quality of life in prostate cancer: progress and challenges. In: Lipscomb J, Gotay CC, Snyder C, eds. Outcomes Assessment in Cancer: Measures, Methods, and Applications. Cambridge, UK: Cambridge University Press; 2005:126-160.
14. Wu AW, Snyder C, Clancy CM, et al. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood). 2010; 29:1863-1871.
15. Valderas JM, Alonso J. Patient reported outcome measures: a modelbased classification system for research and clinical practice. Qual Life Res. 2008;17:1125-1135.
16. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(suppl 3):73-81.
17. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. [see comments.]. [Review]. J Allergy Clin Immunol. 2000;106:17-26. (Pubitemid 30482847)
18. Strand V, Cohen S, Crawford B, et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology. 2004;43:640-647. (Pubitemid 38628197)
19. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
20. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
21. Chang VT, Hwang SS, Feuerman M, et al. The memorial symptom assessment scale short form (MSAS-SF). Cancer. 2000;89:1162-1171.
22. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
23. Radloff LS. The CES-D Scale. Appl Psychol Measure. 1977;1:385-401.
24. Holland JC. Preliminary guidelines for the management of distress. Oncology. 1997;109-114.
25. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
26. Wilkie DJ, Savedra MC, Holzemer WL, et al. Use of the McGill Pain Questionnaire to measure pain: a meta-analysis. Nurs Res. 1990;39:36-41. (Pubitemid 20030666)
27. Ravens-Sieberer U, Erhart M, Rajmil L, et al. Reliability, construct and criterion validity of the KIDSCREEN-10 score: a short measure for children and adolescents' well-being and health-related quality of life. Qual Life Res. 2010;19:1487-1500.
28. Oude Voshaar M, ten Klooster P, Taal E, et al. Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: a systematic review of the literature. Health Qual Life Outcomes. 2011;9:1-13.
29. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.
30. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579. (Pubitemid 23071057)
31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
32. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28:551-558.
33. The American Heritage medical dictionary. 2007. Available at: http://www.credoreference.com/vol/463. Accessed March 1, 2011.
34. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605-613. (Pubitemid 34218856)
35. De Civita M, Dobkin PL, Ehrmann-Feldman D, et al. Development and preliminary reproducibility and validity of the parent adherence report questionnaire: a measure of adherence in juvenile idiopathic arthritis. J Clin Psychol Med Settings. 2005;12:1-12. (Pubitemid 40227531)
36. Agency for Healthcare Research and Quality. CAHPS Survey and reporting kit. AHRQ 2001. Available at: http://archive.ahrq.gov/fund/cahpsupp.htm. Accessed March 22, 2012.
37. Vinorelbine Tartrate (Navelbine) [Package Insert]. Research Triangle Park, NC 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2000/20-388S008-Navelbine-prntlbl.pdf. Accessed March 1, 2011.
38. Copley-Merriman K, Jackson J, Boyer JG, et al. Industry perspective regarding outcomes research in oncology. In: Lipscomb J, Gotay CC, Snyder C, eds. Outcomes Assessment in Cancer. Cambridge, UK; New York: Cambridge University Press; 2005:623-638.
39. Moinpour CM. Measuring quality of life: an emerging science. Semin Oncol. 1994;21(suppl 10):48-60.
40. Shah SN, Sesti AM, Copley-Merriman K, et al. Quality of life terminology included in package inserts for US approved medications. Qual Life Res. 2003;12:1107-1117. (Pubitemid 37386638)
41. Sox HC. Defining comparative effectiveness research: the importance of getting it right. Med Care. 2010;48(suppl):S7-S8.
42. Juniper EF, Jenkins C, Price MJ, et al. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med. 2002;1:435-440. (Pubitemid 37062710)
43. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-1902. (Pubitemid 26196450)
44. Lorig KR, Sobel DS, Ritter PL, et al. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4:256-262.
45. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. (Pubitemid 40051905)
46. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25:5106-5112. (Pubitemid 350232291)
47. O'Connor AM. User Manual- Decisional Conflict Scale. r 1993.
48. [Updated 2010]. Available at: http://www.ohri.ca/DecisionAid/. Accessed August 24, 2011.
49. Gotay CC, Pagano IS. Assessment of Survivor Concerns (ASC): a newly proposed brief questionnaire. Health Qual Life Outcomes. 2007;5:15.
50. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28:1671-1676.
51. Pickard AS, Wilke CT, Lin HW, et al. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics. 2007;25:365-384. (Pubitemid 46744468)
52. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007;12:631-635. (Pubitemid 47036199)
53. Ramsey SD, Barlow WE, Moinpour C, et al. Incorporating comparative effectiveness research study endpoints into the treatment for positivenode, endocrine-responsive breast cancer (RxPONDER) study. ASCO Meeting Abstracts. 2011;29(suppl):TPS101.
54. Clinical Trials (PDQs) 2011. Available at: http://www.cancer.gov/ clinicaltrials/search/view/print?cdrid = 692475&version = HealthProfessional& protocolsearchid = 9102639. Accessed May 24, 2011.
55. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865-869.
56. National Cancer Institute. Patient-reported outcomes version of the common terminology criteria for adverse events. PRO-CTCAE Wiki Website Overall Homepage 2011. Available at: https://wiki.nci.nih. gov/x/cKul. Accessed March 1, 2011.
57. Basch EM, Reeve BB, Cleeland CS, et al. Development of the patientreported version of the common terminology criteria for adverse events (PRO-CTCAE). J Clin Oncol. 2010;28: (suppl)abstr e19605.
58. Snyder C, Aaronson N, Choucair A, et al. Implementing patientreported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2011;1-10. DOI: http://dx.doi.org/10.1007/s11136- 011-0054-x.
59. Basch E, Abernethy AP. Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol. 2011;29:954-956.
60. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2:113-127.
61. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inform J. 2002;36:209-238. (Pubitemid 34208219)
62. Emery MP, Perrier LL, Acquadro C. Patient-reported outcome and quality of life instruments database (PROQOLID): frequently asked questions. Health Qual Life Outcomes. 2005;3:12.
63. World Health Organisation. International Classification of Functioning, Disability and Health (ICF). WHO 2010. Available at: http://www.whofic-apn.com/ pdf-files/05/ICF.pdf. Accessed March 22, 2012.
64. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59-65.
65. Brennan PF, Downs S, Casper G, et al. Project Health Design: stimulating the next generation of personal health records. AMIA Annual Symposium Proceedings/AMIA Symposium 2007;70-74.
66. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patientreported outcomes. J Clin Epidemiol. 2010;63:737-745.
67. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22.
68. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19:539-549.
69. Mokkink LB, Terwee CB, Knol DL, et al. Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments. BMC Med Res Methodol. 2006;6:2.
70. Snyder CF, Watson ME, Jackson JD, et al. Patient-reported outcome instrument selection: designing a measurement strategy. Value Health. 2007;10(suppl 2):S76-S85. (Pubitemid 350098924)
71. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83.
72. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832-838. (Pubitemid 23093803)
73. Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J Clin Epidemiol. 1993;46:1103-1111. (Pubitemid 23302077)
74. Rowe BH, Oxman AD. Performance of an asthma quality of life questionnaire in an outpatient setting. Am Rev Respir Dis. 1993; 148:675-681. (Pubitemid 23263779)
75. Rutishauser C, Sawyer SM, Bond L, et al. Development and validation of the Adolescent Asthma Quality of Life Questionnaire (AAQOL). Eur Respir J. 2001;17:52-58. (Pubitemid 32600556)
76. Horn SD, Gassaway J. Practice-based evidence study design for comparative effectiveness research. [Review]. Med Care. 2007; 45(suppl 2):S50-S57.
77. Donaldson G. Patient-reported outcomes and the mandate of measurement. Qual Life Res. 2008;17:1303-1313.
78. Resolution of the World Health Assembly, WHA54.21: International classification of functioning, disability and health. World Health Organization 2001. Available at: http://www.who.int/classifications/icf/wha-en.pdf. Accessed February 15, 2011.
79. Ustun TB, Chatterji S, Kostansjek N, et al. and functional status information in health records. Health Care Financ Rev. 2003;24:77-88. (Pubitemid 36807762)
80. Ware JE Jr., Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre; 1993.
81. The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46:1569-1585.
82. Feeny D, Furlong W, Barr RD. Multiattribute approach to the assessment of health-related quality of life: Health Utilities Index. Med Pediatr Oncol. 1998;1(suppl):54-59.
83. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and singleattribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40:113-128.
84. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics. 1998; 13:421-433. (Pubitemid 28140701)
85. Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48:1531-1548. (Pubitemid 29254112)
86. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220. (Pubitemid 40353904)
87. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics. 1995;7:503-520.
88. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996;34:702-722. (Pubitemid 126433265)
89. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873-884. (Pubitemid 39264234)
90. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523-1532. (Pubitemid 40848233)
91. Rabin R, de CF. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343. (Pubitemid 32675374)
92. Frosch DL, Kaplan RM, Ganiats TG, et al. Validity of selfadministered quality of well-being scale in musculoskeletal disease. Arthritis Rheumatism. 2004;51:28-33. (Pubitemid 38222279)
93. Kaplan RM, Ganiats TG, Sieber WJ, et al. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care. 1998;10:509-520. (Pubitemid 29037244)
94. Gold M, Siegel J, Russell LB, et al. Cost Effectiveness in Health and Medicine. New York: Oxford University; 1996.
95. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med. 2008;148:956-961.
96. The World Health Organization Quality of Life Assessment (WHOQOL). Development and general psychometric properties. Soc Sci Med. 1998;46:1569-1585.
97. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
98. Pressler SJ, Eckert GJ, Morrison GC, et al. Evaluation of the Health Utilities Index Mark-3 in heart failure. J Card Fail. 2011;17: 143-150.
99. Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33:375-384. (Pubitemid 32675379)
100. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72. (Pubitemid 26191458)
101. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851-859. (Pubitemid 39456916)
102. Brazier JE, Roberts JR, Deverill M. The estimation of a preferencebased measure of health from the SF-36. J Health Econ. 2002;21: 271-292. (Pubitemid 34143147)
103. Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med Care. 1979;17:501-525. (Pubitemid 9192559)
104. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991; 29:786-798.
105. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493. (Pubitemid 27431704)
106. Holmes WC, Shea JA. Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV. Qual Life Res. 1999;8:515-527. (Pubitemid 29470621)
107. O'Leary JF, Ganz PA, Wu AW, et al. Toward a better understanding of health-related quality of life: a comparison of the Medical Outcomes Study HIV Health Survey (MOS-HIV) and the HIV Overview of Problems-Evaluation System (HOPES). J Acquire Immune Defic Syndr Hum Retrovirol. 1998;17:433-441.
108. WHOQOL HIV Group. WHOQOL-HIV for quality of life assessment among people living with HIV and AIDS: results from the field test. AIDS Care. 2004;16:882-889.
109. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy- Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55: 285-295. (Pubitemid 34195525)
110. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11:207-221. (Pubitemid 34553502)
111. Cormier JN, Ross MI, Gershenwald JE, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008;112:2249-2257. (Pubitemid 351628636)
112. Groenvold M, Klee MC, Sprangers MA, et al. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50:441-450. (Pubitemid 27223274)
113. Lenderking WR, Testa MA, Katzenstein D, et al. Measuring quality of life in early HIV disease: the modular approach. Qual Life Res. 1997;6:515-530. (Pubitemid 27431707)
114. Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45(suppl 1):S3-S11.
115. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005- 2008. J Clin Epidemiol. 2010;63:1179-1194.
116. Bharmal M, Thomas J III. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health. 2006;9:262-271. (Pubitemid 44126781)
117. Hollingworth W, Deyo RA, Sullivan SD, et al. The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ. 2002;11:71-85. (Pubitemid 34097623)
118. Suarez-Almazor ME, Kendall C, Johnson JA, et al. Use of health status measures in patients with low back pain in clinical settings. Comparison of specific, generic and preference-based instruments. Rheumatology (Oxford). 2000;39:783-790. (Pubitemid 30487902)
119. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res. 2004;13:115-138. (Pubitemid 38379776)
120. Revicki DA, Fairclough D. Preventing missing data. In: Fayers P, Hays RD, eds. Assessing Quality of Life in Clinical Trials. 2nd ed. New York: Oxford University Press; 2005.
121. Donaldson GW, Moinpour CM. Learning to live with missing qualityof- life data in advanced-stage disease trials. J Clin Oncol. 2005;23: 7380-7384. (Pubitemid 46291794)
122. Lipscomb J, Donaldson MS, Arora NK, et al. Cancer outcomes research. J Natl Cancer Inst Monogr. 2004;33:178-197.
123. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102-109.
124. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
125. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
126. Zhou YY, Garrido T, Chin HL, et al. Patient access to an electronic health record with secure messaging: impact on primary care utilization. Am J Manag Care. 2007;13:418-424. (Pubitemid 47080806)
127. Zhou YY, Unitan R, Wang JJ, et al. Improving population care with an integrated electronic panel support tool. Popul Health Manag. 2011;14:3-9.
128. Mazor KM, Sabin JE, Goff SL, et al. Cluster randomized trials to study the comparative effectiveness of therapeutics: stakeholders' concerns and recommendations. Pharmacoepidemiol Drug Saf. 2009;18: 554-561.
129. Black N, Devlin N, Kazis LE. The Routine Use of Patient-reported Outcomes Measures in Health Service Decision Making: Challenges and Opportunities. ISOQOL Annual Conference 2010. Available at: http://www.isoqol.org/pdfs/ ISOQOLProgram2010.pdf. Accessed January 13, 2011.
130. Canadian Community Health Survey (CCHS)- Healthy Aging. Statistics Canada 2010. Available at: http://www.statcan.gc.ca/imdb-bmdi/instrument/5146-Q1-V2- eng.pdf. Accessed August 25, 2011.
131. Swain L, Catlin G, Beaudet MP. The National Population Health Survey- its longitudinal nature. Health Reports. 1999;10:69-82.
132. FDA. Adverse Event Reporting System. (AERS) 2009. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm. Accessed March 1, 2011.
133. Pearson SD, Bach PB. How medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood). 2010;29:1796-1804.
134. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6:522-531. (Pubitemid 37187713)
135. Patient-Reported Outcomes Research Institute. PCORI, 2011. Available at: http://www.pcori.org/. Accessed March 1, 2011.